1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Price Chart
4. Valuation
5. Offer Terms
6. Financial Statements
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
MGRX
Listed on
2023-03-21
Sector
Health Care
Subsector
Health Care Providers & Services
Offer Price
$4.00
first filed $3.00–$5.00Shares Offered
1.25M
16.02M
$69.3M
7.8%
Implied Upside vs Midpoint
Description
We plan to connect consumers to licensed healthcare professionals through our recently launched website at www.MangoRX.com for the provision of care via telehealth on our customer portal and plan to also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. To date, we have developed what we believe is a go-to-market strategy inclusive of product development, operations, marketing and advertising; however, we have not produced a significant amount of products and have generated only minimal revenues to date. We have identified men’s wellness telemedicine services and products as a growing sector in recent years and especially related to the areas of erectile dysfunction (“ED”) products. We have developed and are currently in the process of preparing to commercially market a new brand of ED product under the brand name “Mango.” This product is produced at a compounding pharmacy and is available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. This product currently includes the following three ingredients: Tadalafil (the active ingredient in Cialis) and Oxytocin, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs; and L-Arginine, an amino acid that is available as a dietary supplement. However, the fact that Tadalafil and Oxytocin are used in FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean that these ingredients will prove safe when combined into a single formulation to treat ED. We currently offer two dosage levels of our Mango ED product and anticipate doctors prescribing a dosage based on the needs and medical history of the patient. Our Mango ED product currently includes the following amounts of the three ingredients discussed above: (1) Tadalafil (10 milligrams (mg)), Oxytocin (100 International units (IU)) and L-Arginine (50mg); and (2) Tadalafil (20mg), Oxytocin (100IU) and L-Arginine (50mg). Our Mango ED product has not been, and will not be, approved by the FDA and instead we plan to produce and sell our products, including our Mango ED product, under an exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act, as discussed below. We are not aware of any clinical studies involving the administration of tadalafil sublingually at the doses we provide patients, or the compounding of tadalafil, oxytocin, and L-arginine to treat ED, as is contemplated by our ED product. We are, however, aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of Tadalafil and Sildenafil (the active ingredient in Viagra). Additionally, because our Mango ED product is being specially compounded for the customer by a pharmacist with a physician’s prescription and because the ingredients for our Mango ED product will be publicly disclosed, this product formula can be replicated by other companies. Because our ED product has not been, and will not be, approved by the FDA, our product has not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death. If this were to occur, we could be subject to litigation and governmental action, which could result in costly litigation, significant fines, judgments or penalties. We currently anticipate using approximately $1.8 million of the net proceeds of this offering to finance the marketing and operational expenses associated with the planned marketing of our Mango ED product. We launched our website in mid-November 2022. To date, we have sold only a small amount of products and generated only minimal revenues. We plan to market and seek to sell commercial quantities of our Mango ED product in the first quarter of 2023 following this offering. Mango has been formulated as a Rapid Dissolve Tablet (“RDT”) using a sublingual (applied under the tongue) delivery system to bypass the stomach and liver. It is a generally established principle that sublingual drug absorption through the oral mucosa is generally faster than drug absorption through the gastrointestinal tract. This is because sublingual drugs that are absorbed through the oral mucosa directly enter the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver (see H. Zhang et al., Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications, 41 Clin Pharmacokinet 661, 662 (2002). Though the active ingredients that comprise our Mango product are meant to treat ED – an issue that according to a 2018 study published in The Journal of Sexual Medicine has been estimated to affect over one-third of today’s men’s population (with prevalence increasing with age) – we are also aiming to brand ourselves as a lifestyle company marketed to men seeking enhanced sexual vitality, performance, and overall mood and confidence. Mango is expected to be sold exclusively online via our recently launched website at www.MangoRX.com. --- Our principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248, and our telephone number is (214) 242-9619. Our principal website address is www.MangoRX.com. The Company was formed as a Texas corporation on October 7, 2021. At the time of the formation of the Company, the Company was wholly-owned by American International. Jacob D. Cohen, our Chairman and Chief Executive Officer, previously held majority voting control over American International through February 15, 2023, and also serves as the Chief Executive Officer, President and a member of the Board of Directors of American International. American International formed the Company with the intent of focusing on developing, marketing and selling a variety of men’s wellness products and services via a telemedicine platform. On June 16, 2022, American International entered into and closed the transactions contemplated by a Stock Purchase Agreement (the “SPA”) with Cohen Enterprises, Inc. (“Cohen Enterprises”), which is owned by Mr. Cohen, the Chairman and Chief Executive Officer of the Company, and who is also the majority shareholder of the Company. American International originally determined to divest its interests in the Company in order to focus on developing its pharmacy business through its 51% ownership of Epiq Scripts (ownership of which has since been transferred to Mr. Cohen, our Chairman and Chief Executive Officer, as discussed above), which entity the Company has entered into the Master Services Agreement with as discussed above.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
Operating margin | -22280% | 2.4% | ||
Net margin | -22352% | -2.4% | ||
Free cash flow margin | -15546% | 4.3% | ||
Net cash / market cap | 1.0% | 0.8% | ||
Debt / equity | 0.00 | 0.00 | ||
Current ratio | 2.67 | 1.58 | ||
Stock comp / revenue | 2619% | 0.5% | ||
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||
= Priced at $4.00, 0% above the midpoint of the first filed range ($3.00–$5.00, 2023-01-13).
Each filing is plotted ahead of the first trading day on the price chart.
| Filed | Form | Price range | Price | Shares offered | Deal size |
|---|---|---|---|---|---|
| 2023-01-13 | S-1 | $3.00–$5.00 | — | 1,250,000 | $5.0M |
| 2023-01-26 | S-1/A | — | $4.00 | 1,250,000 | $5.0M |
| 2023-02-06 | S-1/A | — | $4.00 | 1,250,000 | $5.0M |
| 2023-02-21 | S-1/A | — | $4.00 | 1,250,000 | $5.0M |
| 2023-02-28 | S-1/A | — | $4.00 | 1,250,000 | $5.0M |
| 2023-03-22 | 424B4 | — | $4.00 | 4,765,000 | $19.1M |
| 2023-03-22 | 424B4 | — | $4.00 | 1,250,000 | $5.0M |
Mangoceuticals Inc income statement and balance sheet, FY Dec 2022 to FY Dec 2025, as reported in SEC filings.
| Metric | FY Dec 2022 | FY Dec 2023after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Revenue | $8.9K | $731K | $616K | $456K |
| Gross profit | $4.8K | $432K | $380K | $250K |
| Operating income | ($2.0M) | ($9.2M) | ($8.0M) | ($18.0M) |
| Net income | ($2.0M) | ($9.2M) | ($8.7M) | ($20.6M) |
| Revenue growth | — | 8083% | −15.8% | −26.0% |
| Gross margin | 54.3% | 59.0% | 61.7% | 54.9% |
| Operating margin | −22280% | −1260% | −1294% | −3954% |
| Net margin | −22352% | −1259% | −1414% | −4527% |
| Metric | FY Dec 2022 | FY Dec 2023after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Total assets | $1.0M | $1.1M | $15.4M | $16.1M |
| Total liabilities | $389K | $276K | $1.4M | $891K |
| Total equity | $614K | $775K | $13.9M | $15.2M |
| Cash & equivalents | $683K | $739K | $58.7K | $1.5M |